AptarGroup appoints Virginie Maes before AptarGroup stock results

Published on 10/25/2026 at 00:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AptarGroup names Virginie Maes for January 1, 2027. AptarGroup stock enters October 29 results with USD 1.45-1.53 guidance.

Leadership change meets earnings test

Virginie Maes will lead Aptar Pharma from January 1, 2027.
Second-quarter revenue reached USD 1.03 billion, up 6.30 percent year over year.
Third-quarter results are scheduled for October 29, 2026, with guidance of USD 1.45-1.53 adjusted earnings per share.

ATR, US0383361039, Illustration mit AI erstellt.

AptarGroup (ISIN US0383361039) appointed Virginie Maes as president of Aptar Pharma effective January 1, 2027, according to the company's release dated October 22, 2026. The leadership change arrives before the company's third-quarter results, which are scheduled for October 29, 2026.

Maes takes charge in January

Aptar said Maes will join from Amcor, where she leads a global pharma and medical packaging business. Her remit covers a division built around drug delivery, dosing and protection technologies, making the appointment relevant to Aptar's largest strategic growth area.

The chronology is clear: on July 30, 2026, Aptar reported second-quarter revenue of USD 1.03 billion and adjusted earnings per share of USD 1.42; on October 9, 2026, UBS began coverage with a USD 135.00 target; on October 22, 2026, Aptar announced Maes as the incoming Pharma president. The three dates mark a shift from operating results to expectations and leadership execution.

What does the earnings bar require?

MarketBeat reported that second-quarter revenue rose 6.30 percent year over year, while adjusted earnings per share declined from USD 1.66 in the prior-year quarter to USD 1.42. Management's third-quarter guidance is USD 1.45-1.53 for adjusted earnings per share, putting the lower end only USD 0.03 above the second-quarter result.

The next test is whether Aptar can turn revenue growth into steadier earnings as its Pharma business absorbs the emergency-medicine headwind. A third-quarter consensus of USD 1.47 adjusted earnings per share and USD 980.76 million in revenue sets a measurable bar, according to MarketBeat.

October dates set the test

The company is due to report third-quarter results after the market close on October 29, 2026, with the earnings call scheduled for October 30, 2026, according to MarketBeat. Maes takes over on January 1, 2027, so the report will provide the final operating snapshot before the new Pharma leader begins.

AptarGroup's market capitalization was USD 8.0 billion as of October 23, 2026, while its 52-week range was USD 103.23 to USD 146.91. The valuation leaves the earnings release and the leadership handoff as the clearest near-term tests for the stock.

Company facts and market context

AptarGroup, Inc. operates in healthcare and medical instruments and supplies, with Pharma, Beauty + Home, and Food + Beverage businesses. Its primary listing is on the NYSE under ticker ATR.

The further course of trading is shown by the continuously updated real-time quote of AptarGroup stock.